European Commission Approves Pfizer's Cibinqo® for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis Pharmaceutical Investing
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer Life Science Investing
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i Life Science Investing
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study Pharmaceutical Investing
World Health Organization Strategic Advisory Group of Experts Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster Pharmaceutical Investing
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older Pharmaceutical Investing
VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision , is Now Available Pharmaceutical Investing
BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression Pharmaceutical Investing
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS for the Treatment of Adults With Active Lupus Nephritis Pharmaceutical Investing
